1.	Phase III Randomized Study of Cisplatin-Containing Chemotherapy With Versus Without Bevacizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-E1305, E1305, NCT00588770
2.	Radiotherapy, Cetuximab, and Injections of TNFerade™ Biologic for Elderly or Frail Patients With Head and Neck Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: UCIRB #14735B, GV-001.010 (TNF-ELF), NCT00496236
3.	Phase I/II Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MCC-15461, IND 102483, LBH589, NCT00738751
4.	Study of Sorafenib/Cetux in Head and Neck Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: 1516, NCT00815295
5.	A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in NNSCC Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 90 Sponsor: Other Protocol IDs: J08101, CA180123, NCT00882583
6.	Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GCO # 06-0509, NCT00970502
7.	MLN8237 in Adults With Nonhematological Malignancies, Followed by MLN8237 in Lung, Breast, Head and Neck or Gastroesophageal Malignancies Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: C14007, NCT01045421
8.	Pemetrexed Chemotherapy in Poor-Risk Patients With Advanced Head and Neck Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: OSU-0482, NCT00293579
9.	Use of Cone Beam Kilovaltage Imaging in Patients Receiving Radiation Therapy for Head and Neck Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 06U.195, NCT00358007
10.	Phase II Study of AZD2171 in Patients With Recurrent or Newly Diagnosed Metastatic Squamous Cell Carcinoma of the Head and Neck Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: MGH-06-264, MGH-06-264, 7309, NCT00458978
11.	Fluorouracil, Hydroxyurea, Cetuximab and Twice-Daily Intensity Radiation Therapy for Advanced Head and Neck Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GCO 06-1155, NCT00462735
12.	Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 14401A, NCT00468169
13.	Sorafenib Plus Carboplatin and Paclitaxel in Head and Neck Squamous Cell Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2006-0940, NCT00494182
14.	UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer Phase: Phase II Type: Treatment Status: Active Age: 19 and over Sponsor: Other Protocol IDs: F070824015, UAB 0718, NCT00570232
15.	A Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: J0813, 1 R21 CA135635-01, NCT00894413
16.	Phase I Study of UCN-01 and Irinotecan in Patients With Resistant Solid Tumors or Locally Recurrent or Metastatic Triple-Negative Breast Cancer (Part I Closed to Accrual as of 6/8/2007) Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: UVACC-SCC-0102, WUSM-SCC-0102, NCI-5582, 5582, NCT00031681
17.	Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 06C.46, NCT00405405
18.	Phase I Study Using Sunitinib Plus Radiation Therapy for Cancer Patients Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 06C.549, NCT00437372
19.	LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: SCRI REFMAL 121, NCT00556088
20.	Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: JX594-IV-011, NCT00625456
21.	Four Doses of MAGE Vaccine for Patients With Squamous Cell Carcinoma of the Head and Neck Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: HP-41372, UMGCC 0804, NCT00704041
22.	Phase I Study of Sunitinib Malate, Cetuximab, and Concurrent Radiotherapy in Patients With Locally Advanced, Recurrent, Poor Prognosis Squamous Cell Carcinoma of the Head and Neck Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: UCCRC-16051B, 16051B, 8079, NCT00906360
23.	Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC) Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08-084, NCT00736619
24.	A Phase 1 Study of MLN9708 in Adult Patients With Advanced Nonhematologic Malignancies Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: C16001, NCT00830869
25.	Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08-138, NCT00858663